By: Michael Saerens , Ingeborg Hilderson , Anne Hoorens , Celine Jacobs
Introduction: Pyrexia is a frequent complication of treatment with BRAF and MEK inhibitors. Management includes a full infectious workup, initiation of paracetamol, NSAIDs, dose interruption and steroids. In rare cases pyrexia is refractory to classic management. Pathogenesis of pyrexia shows similarities with familial mediteranian fever, a disease that usually responds well to colchicine.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
